Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States

Abstract

Background Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients. Study design and Methods A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient, outpatient, and before procedures. Results We analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures. Conclusions This survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence-based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.

Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study

“…In the REDS‐III study of current transfusion practice in the United States, more than 58% of all outpatient RBC transfusion encounters had either blood disorders or malignancy as their primary diagnosis, and 75% of these outpatients were over age 50 . Similar to our own cohort and other studies, most outpatient RBC transfusion encounters in the REDS‐III study (92%) involved 1 or 2 units …”

Red blood cell transfusion support and management of secondary iron overload in patients with haematological malignancies in the Netherlands: a survey

“…This is probably due to the widespread belief that a high haemoglobin level is beneficial for patients according to the ‘10/30‐rule’ introduced in 1942, in which a RBC transfusion was suggested in surgical patients when haemoglobin levels drop below 10 g/dl or the haematocrit below 30% . The variation in haemoglobin triggers in our study is also in line with a recently published survey regarding RBC transfusion practice in patients with leukaemia in the United States . Although for our study, the outpatient haemoglobin levels were slightly lower when compared with the inpatient haemoglobin triggers, which is in contrast to the US study.…”

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system–wide patient blood management program

“…Despite hematology being one of the biggest users of blood products, with wide variation in transfusion practice, there are few publications on the impact of a PBM program in hematology patients. Attitudes among physicians have been slow to change .…”

“…9 The implementation of PBM programs, particularly in surgical patients, is associated with reduced transfusion utilization, improved patient outcomes, and reduced costs. 10 Despite hematology being one of the biggest users of blood products, with wide variation in transfusion practice, 11 there are few publications on the impact of a PBM program in hematology patients. Attitudes among physicians have been slow to change.…”